{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T06:39:15Z","timestamp":1698993555140},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We assessed whether comparative efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) plus metformin versus BIAsp 30 monotherapy differed for patients with type 2 diabetes mellitus (T2DM) inadequately controlled with oral antidiabetic drugs with different cardiovascular risk scores and different body mass indexes (BMI) by performing a post hoc analysis of the randomized controlled MERIT study. In the MERIT study, eligible patients were randomized 1:1 to receive BIAsp 30 plus metformin or BIAsp 30 for 16\u00a0weeks. Patients in the 2 treatment groups were classified into \u201clow\u201d and \u201chigh\u201d risk subgroups based on their GloboRisk scores and into \u201cBMI\u2009\u2264\u200926\u00a0kg\/m<jats:sup>2<\/jats:sup>\u201dand \u201cBMI\u2009&gt;\u200926\u00a0kg\/m<jats:sup>2<\/jats:sup>\u201d subgroups. Primary efficacy endpoint was between-treatments comparison of HbA1c changes from baseline for these 2 sets of subgroups. Between-treatments comparisons of secondary efficacy and safety endpoints were also performed. We found that BIAsp 30 plus metformin led to significantly higher percentage of high-risk patients achieving HbA1c target\u2009&lt;\u20097% than BIAsp 30 monotherapy, with an overall comparable safety profile for high-risk patients. Meanwhile, for patients with BMI\u2009\u2264\u200926\u00a0kg\/m<jats:sup>2<\/jats:sup>, compared with BIAsp 30 monotherapy, BIAsp 30 plus metformin led to significantly higher percentages of patients achieving HbA1c target (47.83% vs 28.17%, <jats:italic>P<\/jats:italic>\u2009=\u20090.0165) and composite target of HbA1c\u2009&lt;\u20097% without hypoglycemia or weight gain (20.29% vs 6.85%, <jats:italic>P<\/jats:italic>\u2009=\u20090.0187) and have a slightly better safety profile. In conclusion, for T2DM patients at high CV risk or with BMI\u2009\u2264\u200926\u00a0kg\/m<jats:sup>2<\/jats:sup>, BIAsp 30 plus metformin was preferable to BIAsp 30 monotherapy.<\/jats:p>","DOI":"10.1038\/s41598-021-83410-x","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T09:14:59Z","timestamp":1613812499000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30\u2009+\u2009metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Lixin","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baocheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"83410_CR1","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.amjmed.2010.11.003","volume":"125","author":"B Zinman","year":"2011","unstructured":"Zinman, B. Initial combination therapy for type 2 diabetes mellitus: Is it ready for prime time?. Am. J. Med. 125, S19\u2013S34 (2011).","journal-title":"Am. J. Med."},{"key":"83410_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jsps.2019.11.023","volume":"28","author":"SS Alavudeen","year":"2020","unstructured":"Alavudeen, S. S. et al. Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients. Saudi Pharm. J. 28, 210\u2013214 (2020).","journal-title":"Saudi Pharm. J."},{"key":"83410_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1055\/s-2006-949655","volume":"114","author":"PH Kann","year":"2006","unstructured":"Kann, P. H. et al. Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp. Clin. Endocrinol. Diabetes 114, 527\u2013532 (2006).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"83410_CR4","unstructured":"World Health Organization. Global status report on noncommunicable diseases 2014. http:\/\/apps.who.int\/iris\/bitstream\/10665\/148114\/1\/9789241564854_eng.pdf. (2014)."},{"key":"83410_CR5","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1111\/dom.13454","volume":"20","author":"L Guo","year":"2018","unstructured":"Guo, L. et al. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study. Diabetes Obes. Metab. 20, 2740\u20132747 (2018).","journal-title":"Diabetes Obes. Metab."},{"key":"83410_CR6","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1001\/jama.2017.7596","volume":"317","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 317, 2515\u20132523 (2017).","journal-title":"JAMA"},{"key":"83410_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1590\/S0100-879X2006000400009","volume":"39","author":"CA Mour\u00e3o-J\u00fanior","year":"2006","unstructured":"Mour\u00e3o-J\u00fanior, C. A., S\u00e1, J. R., Guedes, O. M. & Dib, S. A. Effects of metformin on the glycemic control, lipid profile, and arterial blood pressure of type 2 diabetic patients with metabolic syndrome already on insulin. Braz. J. Med. Biol. Res. 39, 489\u2013494 (2006).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"83410_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","volume":"33","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin. Diabetes 33, 97\u2013111 (2015).","journal-title":"Clin. Diabetes"},{"key":"83410_CR9","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.2337\/dc19-S009","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2019. Diabetes Care 42, S90\u2013S102 (2019).","journal-title":"Diabetes Care"},{"key":"83410_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1185\/03007990802586079","volume":"25","author":"C Pan","year":"2009","unstructured":"Pan, C., Yang, W., Jia, W., Weng, J. & Tian, H. Management of Chinese patients with type 2 diabetes, 1998\u20132006: The diabcare-China surveys. Curr. Med. Res. Opin. 25, 39\u201345 (2009).","journal-title":"Curr. Med. Res. Opin."},{"key":"83410_CR11","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669\u20132701 (2018).","journal-title":"Diabetes Care"},{"key":"83410_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11154-016-9351-6","volume":"17","author":"A Cahn","year":"2016","unstructured":"Cahn, A., Cernea, S. & Raz, I. Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. Rev. Endocr. Metab. Disord. 17, 117\u2013127 (2016).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"83410_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF00315466","volume":"44","author":"D Giugliano","year":"1993","unstructured":"Giugliano, D. et al. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors. Eur. J. Clin. Pharmacol. 44, 107\u2013112 (1993).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"83410_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.clinthera.2011.04.006","volume":"33","author":"F Ovalle","year":"2011","unstructured":"Ovalle, F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin. Ther. 33, 393\u2013407 (2011).","journal-title":"Clin. Ther."},{"key":"83410_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1507\/endocrj.K06-162","volume":"54","author":"S Tomioka","year":"2007","unstructured":"Tomioka, S. et al. Clinical characteristics influencing the effectiveness of metformin on Japanese type 2 diabetes receiving sulfonylureas. Endocr. J. 54, 247\u2013253 (2007).","journal-title":"Endocr. J."},{"key":"83410_CR16","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1080\/03007995.2016.1227774","volume":"32","author":"DP Martono","year":"2016","unstructured":"Martono, D. P. et al. Predictors of HbA1c levels in patients initiating metformin. Curr. Med. Res. Opin. 32, 2021\u20132028 (2016).","journal-title":"Curr. Med. Res. Opin."},{"key":"83410_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/dme.13154","volume":"34","author":"J Han","year":"2017","unstructured":"Han, J. et al. Different clinical prognostic factors are associated with improved glycaemic control: Findings from MARCH randomized trial. Diabet. Med. 34, 490\u2013499 (2017).","journal-title":"Diabet. Med."},{"key":"83410_CR18","doi-asserted-by":"publisher","first-page":"e0166625","DOI":"10.1371\/journal.pone.0166625","volume":"11","author":"X Cai","year":"2016","unstructured":"Cai, X. et al. Baseline body mass index and the efficacy of hypoglycemic treatment in type 2 diabetes: A meta-analysis. PLoS ONE 11, e0166625 (2016).","journal-title":"PLoS ONE"},{"key":"83410_CR19","doi-asserted-by":"publisher","first-page":"e57222","DOI":"10.1371\/journal.pone.0057222","volume":"8","author":"L Ji","year":"2013","unstructured":"Ji, L. et al. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: Phase IV open-label trial. PLoS ONE 8, e57222 (2013).","journal-title":"PLoS ONE"},{"key":"83410_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2152\/jmi.59.166","volume":"59","author":"S Sumitani","year":"2012","unstructured":"Sumitani, S. et al. Effectiveness of metformin and lifestyle interventions as an initial treatment in Japanese patients with newly diagnosed type 2 diabetes: A prospective observational study. J. Med. Investig. 59, 166\u2013173 (2012).","journal-title":"J. Med. Investig."},{"key":"83410_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S2213-8587(15)00081-9","volume":"3","author":"K Hajifathalian","year":"2015","unstructured":"Hajifathalian, K. et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): A pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 3, 339\u2013355 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"83410_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-8587(17)30015-3","volume":"5","author":"P Ueda","year":"2017","unstructured":"Ueda, P. et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: A pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 5, 196\u2013213 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"83410_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/dme.13825","volume":"36","author":"S McGurnaghan","year":"2019","unstructured":"McGurnaghan, S. et al. Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: A contemporary analysis. Diabet. Med. 36, 718\u2013725 (2019).","journal-title":"Diabet. Med."},{"key":"83410_CR24","doi-asserted-by":"crossref","unstructured":"World Medical Association. WMA Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects. http:\/\/www.wma.net\/ (2008).","DOI":"10.1515\/9783110208856.233"},{"key":"83410_CR25","unstructured":"China Food and Drug Administration. Good clinical practice of China. http:\/\/www.sda.gov.cn\/WS01\/CL0053\/24473.html (2003)."},{"key":"83410_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1463-1326.2005.00492.x","volume":"8","author":"M Kvapil","year":"2006","unstructured":"Kvapil, M., Swatko, A., Hilberg, C. & Shestakova, M. Biphasic insulin aspart 30 plus metformin: An effective combination in type 2 diabetes. Diabetes Obes. Metab. 8, 39\u201348 (2006).","journal-title":"Diabetes Obes. Metab."},{"key":"83410_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1464-5491.2005.01475.x","volume":"22","author":"IF Douek","year":"2005","unstructured":"Douek, I. F. et al. Continuing metformin when starting insulin in patients with Type 2 diabetes: A double-blind randomized placebo-controlled trial. Diabet. Med. 22, 634\u2013640 (2005).","journal-title":"Diabet. Med."},{"key":"83410_CR28","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1016\/j.clinthera.2007.11.017","volume":"29","author":"O Ushakova","year":"2007","unstructured":"Ushakova, O. et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: A 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clin. Ther. 29, 2374\u20132384 (2007).","journal-title":"Clin. Ther."},{"key":"83410_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF03345673","volume":"32","author":"M Velojic-Golubovic","year":"2009","unstructured":"Velojic-Golubovic, M. et al. Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J. Endocrinol. Investig. 32, 23\u201327 (2009).","journal-title":"J. Endocrinol. Investig."},{"key":"83410_CR30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0168-8227(02)00022-0","volume":"57","author":"PC Tong","year":"2002","unstructured":"Tong, P. C., Chow, C. C., Jorgensen, L. N. & Cockram, C. S. The contribution of metformin to glycaemic control in patients with type 2 diabetes mellitus receiving combination therapy with insulin. Diabetes Res. Clin. Pract. 57, 93\u201398 (2002).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"83410_CR31","first-page":"1","volume":"29","author":"Chinese Society of Endocrinology","year":"2013","unstructured":"Chinese Society of Endocrinology. Chinese expert consensus on the clinical application of insulin for adult type 2 diabetes. Chin. J. Endocrinol. Metab. 29, 1\u20136 (2013).","journal-title":"Chin. J. Endocrinol. Metab."},{"key":"83410_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1089\/dia.2015.0054","volume":"17","author":"L Ji","year":"2015","unstructured":"Ji, L. et al. Observational registry of basal insulin treatment (ORBIT) in patients with type 2 diabetes uncontrolled by oral hypoglycemic agents in China-study design and baseline characteristics. Diabetes Technol. Ther. 17, 735\u2013744 (2015).","journal-title":"Diabetes Technol. Ther."},{"key":"83410_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s13300-015-0137-8","volume":"6","author":"L Ji","year":"2015","unstructured":"Ji, L., Tsai, S. T., Lin, J. & Bhambani, S. National variations in comorbidities, glycosylated hemoglobin reduction, and insulin dosage in Asian patients with type 2 diabetes: The FINE-Asia registry. Diabetes Ther. 6, 519\u2013530 (2015).","journal-title":"Diabetes Ther."},{"key":"83410_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/cen.12730","volume":"2","author":"KP Lee","year":"2015","unstructured":"Lee, K. P. Psycholosocial factors associated with psychological insulin resistance in primary care patients in Hong Kong. J. Clin. Transl. Endocrinol. 2, 157\u2013162 (2015).","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"83410_CR35","unstructured":"Yiu, M. P., Cheung, K. L. & Chan, K.W. A questionnaire study to analyze the reasons of insulin refusal of DM patients on maximum dose of oral hypoglycemic agents (OHA) among 3 GOPC in Kowloon West Cluster. http:\/\/www.ha.org.hk\/haconvention\/hac2010\/proceedings\/pdf\/Poster\/spp-p5-38.pdf (2010)."},{"key":"83410_CR36","doi-asserted-by":"publisher","first-page":"e1002026","DOI":"10.1371\/journal.pmed.1002026","volume":"13","author":"F Bragg","year":"2016","unstructured":"Bragg, F. et al. Risks and population burden of cardiovascular diseases associated with diabetes in China: A prospective study of 05 million adults. PLoS Med. 13, e1002026 (2016).","journal-title":"PLoS Med."},{"key":"83410_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/dia.2011.0168","volume":"14","author":"Y Gu","year":"2009","unstructured":"Gu, Y. et al. The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs. Diabetes Technol. Ther. 14, 244\u2013250 (2009).","journal-title":"Diabetes Technol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83410-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:50:35Z","timestamp":1670039435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83410-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83410"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83410-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"6 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L. G. received research funding from Merck Serono Co. Ltd. China. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4131"}}